title: Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial).
abstract: 1680 participants were randomized over the recruitment period in MAPT study. A total of 1290 participants were recruited in the 7 University Hospital centers, and 390 participants in the 6 memory clinics around Toulouse Gerontopole / Alzheimer Disease research clinical center. The first randomization was on May 30, 2008, and the targeted number of randomized participants was reached on February 24, 2011; 2595 subjects were finally screened, of which 1680 fulfilled the eligibility criteria which represents 64.8%. Approximately, one quarter of screened people refused to participate after the detailed presentation of the study and 4.3% were still interested in participating but missed for unknown reasons the baseline visit even after repeated contacts.  Of the 1810 subjects who signed the consent for participating to the study at the baseline visit, 130 (7.1%) were excluded because one of the eligibility criteria was not satisfied. Interestingly, the higher percentage of randomizations compared to screened participants is the personal contact source; almost 85 % of screened participants entered in the study. In an equivalent way, Medias and conferences are efficient recruiting sources to enrol volunteers in the study. Unexpectedly, only about 60% of screened participants from the hospital and GP sources were randomized and 33.2% from health care services. Almost a quarter of the randomized participants come from the hospital outpatients clinics and approximately 20% from public conferences. A total of 1128 contacts yielded to 556 screened volunteers and 345 randomized participants in the coordinating center of Toulouse. Thus, 30 % of contacts were recruited.
authors.affiliation: Gérontopôle, Departement of Geriatrics, CHU Toulouse, Purpan University Hospital, Toulouse, France.
authors.forename: I
authors.initials: I
authors.lastname: Carrié
authors.forename: G Abellan
authors.initials: GA
authors.lastname: van Kan
authors.forename: S
authors.initials: S
authors.lastname: Gillette-Guyonnet
authors.forename: S
authors.initials: S
authors.lastname: Andrieu
authors.forename: J-F
authors.initials: JF
authors.lastname: Dartigues
authors.forename: J
authors.initials: J
authors.lastname: Touchon
authors.forename: T
authors.initials: T
authors.lastname: Dantoine
authors.forename: O
authors.initials: O
authors.lastname: Rouaud
authors.forename: M
authors.initials: M
authors.lastname: Bonnefoy
authors.forename: P
authors.initials: P
authors.lastname: Robert
authors.forename: M-N
authors.initials: MN
authors.lastname: Cuffi
authors.forename: L
authors.initials: L
authors.lastname: Bories
authors.forename: S
authors.initials: S
authors.lastname: Bordes
authors.forename: Y
authors.initials: Y
authors.lastname: Gasnier
authors.forename: F
authors.initials: F
authors.lastname: Desclaux
authors.forename: K
authors.initials: K
authors.lastname: Sudres
authors.forename: A
authors.initials: A
authors.lastname: Pesce
authors.forename: B
authors.initials: B
authors.lastname: Vellas
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control*; D004311:Double-Blind Method; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D017144:Focus Groups; D006801:Humans; D010349:Patient Compliance; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012107:Research Design
chemical_list: D015525:Fatty Acids, Omega-3